Dr. Lynn Kirkpatrick, CEO, commented, "Our focus remains on execution and advancing clinical development plans for our programs that provide strong pain relief using our PF614 and PF614-MPAR drug products. This has been evident in the recently released news regarding completion of enrollment of our first PF614-MPAR study and completion of the clinical stage of two human abuse potential studies for PF614. These studies add to the clinical support demonstrating that Ensysce has a novel approach for delivering effective pain management and safely alleviating severe pain in patients requiring an opioid analgesic. These recent accomplishments move us closer to our Phase 3 plans and toward bringing what we believe is the ‘Next Generation of Analgesia’ for severe pain to commercialization."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENSC:
- Ensysce Biosciences, Inc. (ENSC) Q4 Earnings Cheat Sheet
- Ensysce Biosciences completes enrollment of PF614-MPAR-101 Phase 1 study
- Ensysce Biosciences announces database lock for HAP study of PF614
- Ensysce Biosciences CEO says mindful of potential shareholder dilution
- Ensysce to present overdose protection program at NIH HEAL Meeting